Clinical Laserthermia Systems AB (publ)

Stockholm Stock Exchange CLS-B.ST

Clinical Laserthermia Systems AB (publ) Operating Income for the year ending December 31, 2023: USD -6.51 M

Clinical Laserthermia Systems AB (publ) Operating Income is USD -6.51 M for the year ending December 31, 2023, a -1.04% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • Clinical Laserthermia Systems AB (publ) Operating Income for the year ending December 31, 2022 was USD -6.44 M, a 3.60% change year over year.
  • Clinical Laserthermia Systems AB (publ) Operating Income for the year ending December 31, 2021 was USD -6.68 M, a -6.40% change year over year.
  • Clinical Laserthermia Systems AB (publ) Operating Income for the year ending December 31, 2020 was USD -6.28 M, a -39.47% change year over year.
  • Clinical Laserthermia Systems AB (publ) Operating Income for the year ending December 31, 2019 was USD -4.50 M, a -19.64% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
Stockholm Stock Exchange: CLS-B.ST

Clinical Laserthermia Systems AB (publ)

CEO Mr. Dan Johansson Mogren
IPO Date April 16, 2009
Location Sweden
Headquarters Building 405
Employees 17
Sector Health Care
Industries
Description

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

Similar companies

CANTA.ST

Cantargia AB (publ)

USD 0.15

0.09%

StockViz Staff

January 16, 2025

Any question? Send us an email